tbuckley/cabot-search huggingface dataset:
FRI0174 Two-Year Retention Rate of Subcutaneous Anti-Tumor Necrosis Factor Agents for Rheumatoid Arthritis: A Retrospective Analysis of The Lorhen Registry
Authors: E.G. Favalli, R. Caporali, S. Monti, P.C. Sarzi Puttini, F. Atzeni, E. Fusaro, P.A. Rocchetta, G. Paolazzi, R. Pellerito, R. Gorla, L. Sinigaglia
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> To date four subcoutaneus TNF inhibitors (TNFis) have been licensed for the treatment of rheumatoid arthritis (RA). Although data from real-life registries have largely confirmed the favourable long term retention rates of adalimumab (ADA) and etanercept (ETN), data on golimumab (GOL) and certolizumab pegol (CZP) drug survival are still lacking. <h3>Objectives</h3> The aim of the study is to evaluate the 2-year retention rate of TNFis used as 1st or 2nd line biotherapy in RA patients in a multicentric observational cohort (the LORHEN registry). <h3>Methods</h3> Data of all RA patients treated with a TNFi were retrospectively extracted from the LORHEN registry, including a cohort of more than 3000 RA subjects who received at least one biologic agent since 1999. The analysis was limited to patients who received ADA, ETN, CZP, or GOL as first- or second-line biotherapy in the period when all the considered TNFis were available in Italy (from January 2010 to November 2015). The 2-year retention rate was calculated by Kaplan-Meier method and the comparative risk for discontinuation among individual TNFi was compared by a stratified log-rank test. Sub-analyses according to first or second line treatment have been performed. <h3>Results</h3> The study population included 677 RA patients (79.7% female, mean age [±SD] 54.3 [±13.5] years, mean disease duration 8.9 [±8.8] years, mean baseline disease activity score 28 4.9 [±1.3]), treated with a first (n=444) or a second line (n=233) TNFi. In the biologic naïve group, 141 patients received ADA, 88 CZP, 130 ETN, and 85 GOL, whereas in the switcher group 68 patients have been treated with ADA, 38 with CZP, 76 with ETN, and 51 with GOL. The overall 2-year retention rate was 58.5% (63.3 and 49.4% in first- and second-line group, respectively; p&lt;0.001). The 2-year drug survival of individual TNFi was 46% for ADA, 66% for CZP, 56% for ETN, and 53% for GOL (p=0.006 for CZP vs ADA, p=n.s. for other comparisons). Sub-analyses according to line of TNFi treatment demonstrated 2-year retention rate of ADA, ETN, CZP, and GOL to be 57.4, 66.9, 73.9, and 56.5%, respectively (p=0.048 for CZP vs ADA, p=n.s for other comparisons) in biologic naïve patients and 38.2, 46.1, 60.5, and 60.8%, respectively (p=0.017 for GOL vs ADA, p=n.s for other comparisons) in switchers. <h3>Conclusions</h3> In the real-life scenario of the Lorhen registry, overall 2-year retention rate of TNFis was about 60% with a significantly higher persistence in biologic naïve patients compared with switchers. In the comparison among individual TNFis, no significant differences were found with the exception of a lower drug survival of ADA compared with CZP in biologic naïve subjects and with GOL in switchers. <h3>Disclosure of Interest</h3> None declared
Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.
Authors: Bijay Nair, Yiming Zhou, Bart Barlogie, Jeffrey Sawyer, Jackie Szymonifka, John Crowley, John D. Shaughnessy
Journal: Blood (2008)
Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma
Authors: Efstathios Kastritis, Evangelos Terpos, Nikolaos Kanellias, Vasiliki Babali, Spyridon Orfanopoulos, Ursula Koloventzou, Maria Gavriatopoulou, Despoina Fotiou, Dimitrios Ziogas, Eftychia Kafantari, Stavroula Giannouli, Meletios A. Dimopoulos
Journal: Blood (2015)
Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients,
Authors: Martina Kleber, Kerstin Höck, Gabriele Ihorst, Bernd Koch, Ralph Waesch, Monika Engelhardt
Journal: Blood (2011)
SP0117 When and How To Use MRI in Clinical Practice
Authors: K.G. Hermann
Journal: Annals of the Rheumatic Diseases (2016)

MRI is very popular among clinicians and patients are referred to a large extent to radiological facilities to help establishing diagnoses. However, despite MRI is one of the more expensive imaging tests its not automatically the one solving all clinical problems. The lecture will highlight the value of MRI for early diagnosis of both axial and appendicular arthritides. On the other hand, certain diagnostic problems will be outlined that did benefit from additional imaging modalities or from a carefully obtained medical history. Learning objectives: Learn how to use MRI for establishing a diagnosis. Learn how early detection differs from differentiation of arthritides. Identify diseases that do not benefit from MR imaging. <h3>Disclosure of Interest</h3> None declared
Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.
Authors: Frédéric Millot, Andre Baruchel, Joelle Guilhot, Arnaud Petit, Thierry Leblanc, Yves Bertrand, Françoise Mazingue, Lutz Patrick, Cécile Vérité, Christian Berthoux, Claire Galambrun, Frédéric Bernard, Karima Yacouben, Pierre Bordigoni, Christine Edan, Yves Reguerre, Gérard Couillaud, Jean-Michel Cayuela, François Guilhot
Journal: Blood (2009)
Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.
Authors: Allan Lipton, Robert E. Coleman, Pierre Major, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, YinMiao Chen, Yong Jiang, Richard Cook
Journal: Blood (2005)
1st-Line Treatment with R-CHOP-14 or R-CHOP-21 in Patients with High-Grade Non-Hodgkin’s Lymphoma Is Similarly Effective: Data from the German Prospective TLN Registry
Authors: Wolfgang Knauf, Wolfgang Abenhardt, Johannes Mohm, Jacqueline Rauh, Renate Grugel, Johanna Harde, Martina Jänicke, Norbert Marschner
Journal: Blood (2014)
Can Peg-Interferon (IFN) α-2a Eradicate JAK2V617F-Positive Bone Marrow Progenitors in Polycythemia Vera (PV)?
Authors: Jean-Jacques Kiladjian, Sabrina Dupont, Bruno Cassinat, Aline Massé, William Vainchenker, Christine Chomienne, François Delhommeau, Pierre Fenaux
Journal: Blood (2008)
FRI0258 Validation of Bioelectrical Impedance Analysis for The Assessment of Body Composition in Patients with Systemic Sclerosis
Authors: M.J. Spanjer, I.E.M. Bultink, M.A.E. de van der Schueren, A.E. Voskuyl
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Malnutrition is a frequently reported complication in patients with systemic sclerosis (SSc) [1]. Especially low fat free mass (FFM) has been identified a prognostic factor for morbidity and mortality. Different methods are available to assess body composition. Bioelectrical impedance analysis (BIA) is a bedside method that has not yet been validated in this patient group. <h3>Objectives</h3> To validate BIA against whole body dual-energy x-ray absorptiometry (DXA), for the assessment of body composition in patients with SSc. <h3>Methods</h3> Body composition was assessed in 72 patients with whole body DXA (Hologic, Discovery A) and BIA (Bodystat Quadscan 400). The Geneva equation [2] was used to estimate FFM. The agreement between BIA and whole body DXA was assessed with Bland-Altman analysis and intraclass correlation coefficients (ICCs). The occurrence of malnutrition was assessed and defined as fat free mass index (FFMI) ≤14.5 kg/m<sup>2</sup> for women or ≤16.6 kg/m<sup>2</sup> for men [3]. <h3>Results</h3> No difference was found between BIA and whole body DXA for the assessment of FFM as predicted by the Geneva equation (mean difference 0.02 ± 2.4 kg). ICC was 0.97 (95% CI: 0.95–0.98). The 95% limits of agreement, as assessed by Bland-Altman analysis were -4.6 kg and 4.6 kg. Despite normal BMIs (24.6 ± 4.3 kg/m<sup>2</sup>), malnutrition was found in 14 (19.4%) patients with SSc. <h3>Conclusions</h3> This study shows acceptable validity of BIA in determining FFM in patients with SSc on a group level, while on an individual level, FFM may vary by 4.6 kg. This study also demonstrated a high prevalence (19.4%) of malnutrition in patients with SSc, underlining the necessity of assessing body composition in this patient group. <h3>References</h3> Harrison E, et al. Rheumatology. 2012;51:1747–56 Kyle UG, et al. Nutrition. 2001;17:248–53. Schutz Y, et al. Int J Obes Relat Metab Disord. 2002;26:953–60 <h3>Disclosure of Interest</h3> None declared
A Novel EGLN1/PHD2 High-Frequency Variant in Tibetans Protects Against Hypoxia-Induced Polycythemia.
Authors: Felipe R Lorenzo V, Chad Daniel Huff, Mikko Myllymäki, Sabina Swierczek, Mohamed E Salama, Gregg Semenza, Victor R. Gordeuk, Lynn Jorde, Peppi Koivunen, Josef T. Prchal
Journal: Blood (2012)
Evaluation of Serum Lactate Dehydrogenase and Soluble Interleukin-2 Receptor in Malignant Lymphoma
Authors: Naoto Tomita, Masataka Taguri, Chizuko Hashimoto, Hirotaka Taksaki, Katsumichi Fujimaki, Shigeki Motomura, Hideyuki Koharazawa, Sachiya Takemura, Hiroyuki Fujita, Etsuko Yamazaki, Rika Kawasaki, Jun Taguchi, Rika Sakai, Shin Fujisawa, Yukako Hattori, Heiwa Kanamori, Wataru Yamamoto, Hiroshi Harano, Koji Ogawa, Yoshiaki Ishigatsubo
Journal: Blood (2014)
SAT0556 Utility and Pitfalls of The FRAX® Tool Results in Brazilian Elderly Population
Authors: O.B. Malheiro, M.A.M. Maia, C.J. Machado, E.N. de Moraes, A.M. Kakehasi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Fracture Risk Assessment Tool (FRAX®) was introduced by the World Health Organization (WHO) to estimate the 10-year probability of osteoporotic fractures in untreated patients with osteopenia<sup>1</sup>. This tool is validated for Brazilian population since 2013 but the applicability in this developing country has not been confirmed. <h3>Objectives</h3> To compare the indication for pharmacological treatment in a Brazilian elderly population considering the results of FRAX® with bone mineral density (FRAX®/BMD), FRAX® without BMD (FRAX®) and of BMD classification according to the WHO. <h3>Methods</h3> The study population consisted of patients over 60 years of age from primary care units who had clinical indication for BMD assessment. BMD was undertaken at lumbar spine and femur by dual-energy X-ray absorptiometry (DXA) Hologic Discovery W system (Madison USA, software version 3.3.01) and BMD results were classified according to the WHO criteria. Clinical data was obtained from patient records (secondary osteoporosis, smoking, alcohol consumption, use of glucocorticoids, rheumatoid arthritis, family history (father or mother) with hip fracture, and previous history of fracture) and the 10-year probability of hip and major fractures was calculated using FRAX® tool. Receiving operator curve (ROC) analysis, model calibration and decision curve analysis were used to compare fracture prediction in FRAX® and FRAX®/BMD groups. <h3>Results</h3> 1,000 subjects were included, mean age 76.4 years, 755 (75.5%) women. Osteoporosis, osteopenia and normal BMD were found in 439 (43.9%), 426 (42.6%) e 135 (13.5%) patients, respectively. One hundred and nine (10.9%) patients have already suffered a fragility fracture and 40 of those individuals presented with normal BMD or osteopenia. In 366 (36.6%) patients it was not possible to calculate FRAX® score due to inability of recollection. The application of FRAX® tool would lead to the indication of treatment for 40% of the osteopenic patients and for 62.4% of the osteoporotic patients. Correlations between FRAX and FRAX/BMD were positive and statistically significant for both the 10-year probability of hip fracture and major fracture (0.704 and 0.594, respectively, p&lt;0.001). ROC curve analysis showed that the FRAX/BMD was superior in identifying patients at risk of hip (Figure 1) and major fractures. <h3>Conclusions</h3> Despite the easy access and simplicity of FRAX® it is not possible to disregard the DXA, especially for patients with risk factor for fragility fractures. <h3>References</h3> WHO Scientific group on the assessment of osteoporosis at primary health care level, 2004. www.who.int/chp/topics/Osteoporosis.pdf <h3>Disclosure of Interest</h3> None declared
Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On Eμ-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo
Authors: Fabienne McClanahan, Cristina Ghirelli, Paul Greaves, John C. Riches, Rita Coutinho, Alan G. Ramsay, John G Gribben
Journal: Blood (2012)
AB0756 Living with Osteoarthritis: Real Life Perception upon Pain and Function
Authors: I. Saulescu, C. Coltoiu, A. Neagu, A. Borangiu, D. Opris, S. Daia-Iliescu, V. Bojinca, A. Balanescu, R. Ionescu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoarthritis (OA) is a prevalent condition for which treatments are based on analgesia and physical therapies. Despite that, most of the patients continue to have pain and limited function influencing there day by day life. <h3>Objectives</h3> Our objective was to evaluate pain perception in a cohort of participants, diagnosed with osteoarthritis. <h3>Methods</h3> 75 patients with osteoarthritis were enrolled in this study, conducted in Sf. Maria Hospital between 1 June and 30 December 2015. All patients signed an informed consent approved by local ethic committee. Data about demographics, joint involvement and treatment were collected. All patients completed a HAQ evaluation and a Visual Analogue Scale (VAS) for pain (0–10). We developed a questionnaire in order to capture patient perception about osteoarthritis symptoms and how this disease impact there life. They were asked about how pain interfere with usual activity (work, preparing meal, house kipping), with social activity (family interaction, friends) or how they perceived pain or efficacy of the treatment in the last month. They were also asked about there expectations related to this disease. Statistical analysis was made with SPSS. <h3>Results</h3> Mean age at evaluation was 63 with a female predominance (83%). 89.3% were taking NSAIDs and 73.3% acetaminophen. Functional status evaluated by HAQ showed that 24% patients had a score of 0, with 57% having a score of 1 and 19% a score of 2. VAS for pain was at least 5 for more than 80% of patients, despite treatment. Higher VAS was significant more frequent in female patients (p 0.001), in patients with family history of osteoarthritis (p 0.023) and in the one with sedentary life style (p 0.035). Most of the patients considered that pain interfere with daily activity, the impact being evaluated as moderate for 46.67% of patients and severe for 32%. Pain also had a negative impact on their social life, the percentage for moderate disturbance being of 38.67% and 18.67% for severe one. Only 11% of patients consider that the pain control is well managed. Despite these results, 40% of the patients do not expect that there quality of life will improve in the future. <h3>Conclusions</h3> Residual pain after treatment is present in most of the patients with osteoarthritis and these interfere significantly with daily living and quality of life. These patients enter in a vicious cycle related to worsening pain – low physical activity. Although this findings, there is a resumption of these patients in front of the disease. <h3>References</h3> Neogi T, The epidemiology and impact of pain in osteoarthritis, Osteoarthritis and cartilage, 2013, 21: 1145–1153. <h3>Disclosure of Interest</h3> None declared
Progression Free Survival Is Predicated by Categorical Response, and Supports the Attainment of VGPR/CR as An Objective for Long Term Disease Control in Waldenstrom's Macroglobulinemia.
Authors: Steven Treon, Thea Ioakimidis, Christina Hanzis, Robert Manning, Christopher J Patterson, Zachary Hunter, Patricia Sheehy, Barry Turnbull
Journal: Blood (2009)
MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.
Authors: Sonia Vallet, Noopur Raje, Kenji Ishitsuka, Teru Hideshima, Klaus Podar, Petter Veiby, Iris Breitkreutz, Tanyel Kizeltepe, Hiroshi Yasui, Enrique M. Ocio, Norihiko Shiraishi, Marco Ladetto, Mario Boccadoro, Kenneth C. Anderson
Journal: Blood (2006)
Amoxicillin dosing recommendations are very different in European countries: a cross-sectional survey
Authors: C. Pulcini, B. Beovic, P. Cavalié, A. Deptula, O. Dyar, I. Gyssens, W. Kern, V. Knepper, D. Kofteridis, H. Hanberger, B. Huttner, P. Messiaen, L. Pagani, J. Pano Pardo, C. Pulcini, J. Rodriguez-Bano, G. Skov Simonsen, V. Vlahović-Palčevski, P. Zarb
Journal: Clinical Microbiology and Infection (2016)
Allogeneic Hematopoietic Stem Cell Transplantation for T-Prolymphocytic leukemia: A Retrospective Analysis From the Societe française De Greffe De Moelle Et De Therapie Cellulaire
Authors: Thierry Guillaume, Yves Beguin, Véronique Leblond, Didier Blaise, Noel Milpied, Eric Deconinck, Catherine Cordonnier, Jerome Cornillon, Nathalie Contentin, Gaelle Guillerm, Nathalie Fegueux, Pascal Turlure, Alexandra Salmon, Thierry de Revel, Mohamad Mohty
Journal: Blood (2012)
PTU-155 Endoscopic Management of Granular Cell Tumours Arising in The Oesophagus: A Single Centre Experience
Authors: N Jawad, F Norris, J Solomon, M Novelli, L Lovat, R Haidry
Journal: Gut (2016)

<h3>Introduction</h3> Granular cell tumours (GCTs) are rare and originate from Schwann cells of the nervous system. They are most commonly found in the tongue and breast. GCTs can form anywhere in the gastrointestinal tract and biliary tree but most commonly in the oesophagus. They occur primarily in adults, and more commonly in females and blacks. GCTs are asymptomatic and tend to be incidental findings at endoscopy. GCTs represent 1% of benign oesophageal tumours and have a small risk of malignant transformation when they are greater than 4 cm or exhibit signs of recent growth. Most are in the middle or distal oesophagus and are small appearing as nodules or polyps that are yellow with an intact overlying mucosa. Typically they are single but may be multiple. Histologically they appear as sheets of cells with abdundant eosinophilic granular cytoplasm and small pyknotic nuclei and usually confined to the lamina propria but may invade submucosa and muscularis propria. They are periodic acid shiff (PAS) and S100 positive on immunostaining. Importantly the squamous epithelium overlying the lesion can show pseudo epitheliomatous hyperplasia that may mimic dysplasia or malignancy. <h3>Methods</h3> A retrospective search of the UCLH endoscopy and pathology databases from 2002–2015 identified all cases of oesophageal GCTs on histological analysis from biopsies. Patient’s medical records were reviewed for demographic data, symptoms, endoscopic findings and management plans. <h3>Results</h3> Eleven cases of GCTs in the oesophagus (4 male and 7 female) were identified. Diagnosis was proven on histological analysis of biopsies and positivity for the S-100 protein. Patients were 29–65 years old (mean 46.2 years). Tumour diameter was 0.4–2.0 cm. All GCTs were found in the distal oesophagus. Nine of the lesions were confined to the mucosa/submucosa and two extended into the muscularis propria. The most common presenting symptoms for the index endoscopy were dyspepsia and dysphagia. Eight patients were treated by endoscopic mucosal resection (EMR). One patient had multifocal oesophageal GCTs. All patients had no residual GCT at follow up endoscopy and were discharged. Two patients with GCTs were monitored by 2 yearly surveillance endoscopy and endoscopic ulstrasound (EUS) to ensure no change in lesion size occurred. One patient had an oesophagogastrectomy for treatment of an adenocarcinoma and the GCT was an incidental finding. <h3>Conclusion</h3> Histology demonstrating a deep infiltrative appearing pattern may prompt concern for malignancy. Surveillance endoscopy is advised for asymptomatic GCTs. GCTs that are not excised should be monitored by endoscopy and EUS for any size increase 1–2 yearly. EMR can be performed for small tumours limited to the mucosa safely and successfully. <h3>Disclosure of Interest</h3> None Declared
Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation: Comparison with Viral Infectious Pneumonia
Authors: Sachiko Seo, Jeffrey Yu, Isaac C Jenkins, Terry L Stevens-Ayers, Kuypers M Jane, Huang Meei-Li, Wendy M Leisenring, Keith R Jerome, Sophie Paczesny, Michael Boeckh
Journal: Blood (2015)
Quantitative Dynamics of Flow Cytometric Aberrancies during Treatment with Erythropoietin/G-CSF Are Predictive for Responses in LOW/INT-I Risk Myelodysplastic Syndromes.
Authors: Theresia M Westers, Canan Alhan, Claudia Cali, Gert J Ossenkoppele, Arjan A van de Loosdrecht
Journal: Blood (2008)
Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.
Authors: Yutaka Okawa, Teru Hideshima, Hiroshi Ikeda, Sonia Vallet, Tanyel Kiziltepe, Noopur Raje, Hiroshi Yasui, Sotaro Enatsu, Samantha Pozzi, Iris Breitkreutz, Klaus Podar, Paul G. Richardson, Kenneth C. Anderson
Journal: Blood (2007)
AB1062 Investigation of Interaction between Hand Dexterity and Parental Attitude in Children with Juvenile Idiopathic Arthritis
Authors: U. Berberoğlu, E. Ünal, P. Dizmek, G. Arın, Y. Bilginer, E.D. Batu, Z.S. Arıcı, H.E. Sönmez, S. Özen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There was a gap in the literature about the reason of high prevalence of hand- and wrist-related symptoms in children with juvenile idiopathic arthritis (1). <h3>Objectives</h3> This study was planned for investigate hand dexterity and the relationship between children9s hand dexterity and parental attitude in children with Juvenil Idiopathic Arthritis (JIA). <h3>Methods</h3> 34 children with JIA (according to International League Aganist Rheumatism (ILAR) Classification) and 38 healthy children that matched according to age, sex and hand dominance. 9 Hole Peg Test (9PHT) and Functional Dexterity Test (FDT) were used to evaluate hand dexterity for both groups (2,3). Childhood Health Assessment Questionnaire (CHAQ) was applied for assessing daily living activities (4). Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI) and State and Trait Anxiety Inventory (STAI) were applied to investigate parental attitude. <h3>Results</h3> There was no difference between hand dexterity values of two groups (p&gt;0.05). There was no relationship between Hand Dexterity Scores and CHAQ, BDI, BAI, STAI. <h3>Conclusions</h3> Consequently, the result of the tests we used have shown that hand dexterity was not affected by parental attitude. <h3>References</h3> Hoeksma, A.F., Van Rossum, M.A.J., Zinger, W.G.W., Dolman, K.M., Dekker, J.,Roorda, L.D. (2014) High prevalence of hand- and wrist-related symptoms, impairments, activity limitations and participation restrictions in children with juvenile idiopathic arthritis. Journal of Rehabilitation Medicine, 46 (10), 991–996. Gogola, G.R., Velleman, P.F., Xu, S., Morse, A.M., Lacy, B.,Aaron, D. (2013) Hand dexterity in children: Administration and normative values of the functional dexterity test. Journal of Hand Surgery, 38 (12), 2426–2431. Poole, J.L., Burtner, P.A., Torres, T.A., McMullen, C.K., Markham, A., Marcum, M.L. et al. (2005) Measuring Dexterity in Children Using the Nine-hole Peg Test. Journal of Hand Therapy, 18 (3), 348–351. Ozdogan, H., Ruperto, N., Kasapcopur, O., Bakkaloglu, A., Arisoy, N., Ozen, S. ve diğerleri. (2001) The Turkish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol, 19 (4 Suppl 23), S158–162. <h3>Disclosure of Interest</h3> None declared